SCHEMBL797419

SCHEMBL797419

CCCc1c(-c2nc(-c3cccc(S(C)(=O)=O)c3)no2)cnn1-c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 11/20 0.55
MAPK14 Q16539 1/20 0.48
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 2/20 0.43
NTRK1 P04629 1/20 0.42
MET P08581 1/20 0.42
PIM1 P11309 1/20 0.42
FGFR1 P11362 1/20 0.42
MAP2K2 P36507 1/20 0.42
FLT3 P36888 1/20 0.42
MAPK8 P45983 1/20 0.42
GSK3B P49841 1/20 0.42
NTRK3 Q16288 1/20 0.42
ALK Q9UM73 1/20 0.42
DYRK1B Q9Y463 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773154 0.75 S1PR1 (0.77) S1PR1MAPK14RAB9AALDH1A1LMNA
SCHEMBL773013 0.71 S1PR1 (1.00) S1PR1CA12CA1CA2CA9
SCHEMBL14973404 0.70 S1PR1 (0.49) S1PR1CA12CA1CA2CA9
SCHEMBL772144 0.69 S1PR1 (0.66) S1PR1CA12CA1CA2CA9
SCHEMBL14973128 0.69 CA9 (0.57) S1PR1CA12CA1CA2CA9
SCHEMBL14973067 0.69 CA9 (0.57) S1PR1CA12CA1CA2CA9
SCHEMBL6603154 0.69 PTGS2 (0.78) RAB9AKMT2AALDH1A1NTRK1MET
SCHEMBL14973261 0.69 CA9 (0.56) S1PR1CA12CA1CA2CA9
SCHEMBL14973020 0.68 S1PR1 (0.45) S1PR1CA12CA1CA2CA9
SCHEMBL772722 0.68 S1PR1 (0.58) S1PR1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440554-B1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2016-10-05 EP disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
WO-2010142628-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO S.A. (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS S1PR1, S1PR3, S1PR2 S1PR1 1/4885MAPK14 2129/4885CA12 4880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.